These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38468630)

  • 1. Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study.
    Zhao QH; Chen J; Chen FD; Ruan HY; Zhang W; Zhou YL; Wang QQ; Xu XL; Feng KF; Guo JZ; Gong SG; Zhang RF; Wang L
    Pulm Circ; 2024 Jan; 14(1):e12351. PubMed ID: 38468630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.
    Hu X; Yuan P; Chen J; Wang S; Zhao H; Wei Y; Fu J; Chen F; Ruan H; Zhang W; Zhou Y; Wang Q; Xu X; Feng K; Guo J; Gong S; Zhang R; Zhao Q; Wang L
    Clin Cardiol; 2024 Feb; 47(2):e24245. PubMed ID: 38402556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.
    Cui X; Lu W; Zhang D; Qie L; Li H; Li X; Liu H; Ji Q
    Front Cardiovasc Med; 2022; 9():991586. PubMed ID: 36204579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.
    Deshwal H; Weinstein T; Salyer R; Thompson J; Cefali F; Fenton R; Bondarsky E; Sulica R
    Ther Adv Respir Dis; 2023; 17():17534666231199693. PubMed ID: 37795626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension.
    van Thor MCJ; Ten Klooster L; Snijder RJ; Post MC; Mager JJ
    Int J Cardiol Heart Vasc; 2019 Mar; 22():163-168. PubMed ID: 30859124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.
    Rossi S; Pietrangelo C; Pierdomenico SD; Giuliani L
    Eur Heart J Case Rep; 2020 Oct; 4(5):1-5. PubMed ID: 33204960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.
    Schweintzger S; Koestenberger M; Schlagenhauf A; Grangl G; Burmas A; Kurath-Koller S; Pocivalnik M; Sallmon H; Baumgartner D; Hansmann G; Gamillscheg A
    Cardiovasc Diagn Ther; 2020 Oct; 10(5):1675-1685. PubMed ID: 33224780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
    Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
    Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
    Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.